Subscribe

Ustekinumab Safe and Effective in PsA

VBCR - April 2013, Volume 2, No 2 - Psoriatic Arthritis

Phase 3 data for the PSUMMIT I and PSUMMIT II clinical trials show that ustekinumab (Stelara) is safe and effective in patients with psoriatic arthritis (PsA), and that the improvement persists over 1 year of treatment.

Ustekinumab is the first new biologic agent in phase 3 clinical trials for the treatment of PsA. The drug is an interleukin (IL)-12 and IL-23 inhibitor, a mechanism that is thought to be specific to PsA and not to other autoimmune arthritic diseases. Ustekinumab is approved by the US Food and Drug Administration for the treatment of psoriasis, and is investigational for PsA. Approximately 20% of patients with psoriasis will develop PsA.

The only drugs currently approved by the FDA for the treatment of PsA are tumor necrosis factor (TNF) inhibitors. “TNF inhibitors are not universally effective, and there is a need for new treatments. The PSUMMIT II data are promising,” said lead investigator Arthur F. Kavanaugh, MD, Professor of Clinical Medicine and Director of the Center for Innovative Therapy at the University of California, San Diego.

Week 24 Data from PSUMMIT II
The phase 2, multicenter, ran­domized, double-blind, placebo-controlled PSUMMIT II trial evaluated 2 doses of ustekinumab given subcutaneously to patients with active PsA who were uncontrolled by 1 to 5 disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and/or TNF inhibitors.
Patients were randomized to receive subcutaneous ustekinumab 45 mg or 90 mg, or placebo, at weeks 0 and 4, and then every 12 weeks.

At week 24, the primary end point of achieving at least the ACR 20% criteria for improvement (ACR20) in the signs and symptoms of PsA was reached in 43.7% of the patients who received the 45-mg dose of ustekinumab and in 43.8% of the patients who received the 90-mg dose, versus 20.2% of the patients who received placebo (P <.001 for both comparisons with placebo).

Among the patients who were previously treated with a TNF inhibitor, 36.7% in the ustekinumab 45-mg group and 34.5% in the ustekinumab 90-mg group met the ACR20 criteria, versus 14.5% of the patients who were given placebo (P <.001 for both comparisons with placebo).

The percentage of patients who achieved at least ACR50 at week 24 was 17.5% for ustekinumab 45 mg and 22.9% for ustekinumab 90 mg, versus 6.7% for placebo (P = .018 for the 45-mg dose versus placebo, and  P = .001 for the 90-mg dose versus placebo).

Significant improvements from baseline to week 24 also were seen  in physical function as measured by the Health Assessment Questionnaire Disability Index for both dosage levels of ustekinumab versus placebo.

Christopher Ritchlin, MD, Professor of Medicine and Director of the Rheumatology Fellowship Program and the Clinical Immunology Research Center at the University of Rochester Medical Center, NY, was the lead investigator of PSUMMIT II.

Week 52 Data from PSUMMIT I
Ustekinumab was superior to placebo in patients with active PsA despite treatment with DMARDs and NSAIDs (but not a TNF inhibitor) at 24 weeks, according to results from the PSUMMIT I trial. New 52-week data from PSUMMIT I showed that this improvement persisted from 24 to 52 weeks in patients who were treated with ustekinumab versus placebo.

Related Items
Effect of Previous Biologic Use on Persistence of Tumor Necrosis Factor Inhibitor Treatment
Erin S. Fenner
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Psoriatic Arthritis
Bimekizumab, an IL-17A and IL-17F Inhibitor, Produces High Responses in Skin and Joints in Patients with Psoriatic Arthritis
Walter Alexander
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Psoriatic Arthritis
Ixekizumab Forges Ahead in Psoriatic Arthritis
Alice Goodman
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Psoriatic Arthritis
IL-6 Inhibitor Shows Promise in Patients with PsA
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Psoriatic Arthritis
Long-Term Benefits Seen in Patients with Psoriatic Arthritis Taking Golimumab
Alice Goodman
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Psoriatic Arthritis
Updated Recommendations for Pharmacologic Treatment of Patients with Psoriatic Arthritis
Rosemary Frei, MSc
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Psoriatic Arthritis
Dramatic Weight Loss Improves Psoriatic Arthritis
Phoebe Starr
VBCR - December 2015, Volume 4, No 6 published on December 15, 2015 in Psoriatic Arthritis
Secukinumab Relieves Disease Burden in Patients with Psoriatic Arthritis
Alice Goodman
VBCR - October 2015, Volume 4, No 5 published on October 27, 2015 in Psoriatic Arthritis
Cost Escalating Rapidly for Biologic Treatment of Psoriatic Arthritis
Rosemary Frei, MSc
VBCR - August 2015, Volume 4, No 4 published on August 26, 2015 in Psoriatic Arthritis
Treatment of Psoriatic Arthritis Explored by Cost-Effectiveness
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Psoriatic Arthritis
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology